Actively Recruiting

Age: 18Years +
All Genders
NCT06607120

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

Led by Zhongda Hospital · Updated on 2024-09-23

950

Participants Needed

1

Research Sites

39 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies.

CONDITIONS

Official Title

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of hepatocellular carcinoma confirmed by radiology, histology, or cytology
  • Barcelona Clinic Liver Cancer (BCLC) stage C with extrahepatic spread and/or macrovascular invasion
  • No prior systemic therapy for HCC, including chemotherapy, targeted therapy, or immunotherapy
  • Use of marketed PD-1/PD-L1 inhibitors and anti-angiogenesis drugs, not limited to HCC approval
  • TACE performed within 3 months before or after first PD-1/PD-L1 inhibitor or anti-angiogenic drug treatment
  • Received at least one cycle of PD-1/PD-L1 inhibitor plus anti-angiogenic drug combination therapy after TACE
  • Presence of repeated measurable intrahepatic lesions
Not Eligible

You will not qualify if you...

  • Diagnosis of cholangiocarcinoma, fibrolamellar, sarcomatoid HCC, or mixed hepatocellular/cholangiocarcinoma subtypes confirmed by histology or pathology
  • Inability to meet the specified combination therapy timing
  • Child-Pugh class C liver function, performance status greater than 2, or severe hepatic encephalopathy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhongda Hospital

Nanjing, Jiangsu, China

Actively Recruiting

Loading map...

Research Team

G

Gao-Jun Teng, M.D

CONTACT

H

Hai-Dong Zhu, M.D

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here